Rabbit Recombinant Monoclonal CPLX2 antibody. Carrier free. Suitable for ICC, Flow Cyt (Intra) and reacts with Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human CPLX2 aa 1 to C-terminus.
Constituents: 100% PBS
ICC | Flow Cyt (Intra) | |
---|---|---|
Human | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/20.00000 - 1/100.00000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/25.00000 - 1/100.00000 | Notes - |
Negatively regulates the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. Positively regulates a late step in exocytosis of various cytoplasmic vesicles, such as synaptic vesicles and other secretory vesicles. Also involved in mast cell exocytosis (By similarity).
Complexin-2, Complexin II, Synaphin-1, CPX II, CPLX2
Rabbit Recombinant Monoclonal CPLX2 antibody. Carrier free. Suitable for ICC, Flow Cyt (Intra) and reacts with Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human CPLX2 aa 1 to C-terminus.
Constituents: 100% PBS
CPLX2 also known as Complexin-2 is a synaptic protein involved in neurotransmitter release mechanism. It has a molecular mass of approximately 15 kDa. CPLX2 is highly expressed in the brain and is particularly abundant in synaptic vesicles of neuronal cells. It interacts with SNARE proteins which play a significant role in the vesicle fusion process. CPLX2 acts as a regulator of neurotransmitter release influencing the balance between excitation and inhibition in synaptic transmission.
CPLX2 functions by interacting with other synaptic proteins to facilitate neurotransmitter release at synapses. It forms a complex with SNARE proteins which are essential for synaptic vesicle fusion with the presynaptic membrane. This interaction ensures precise timing of neurotransmitter release which is critical for neural communication. CPLX2’s role in synaptic function highlights its importance in maintaining the efficiency of synaptic signaling.
The role of CPLX2 is integral in synaptic vesicle cycle and neurotransmission pathways. It closely interacts with SNARE proteins such as Syntaxin and Synaptobrevin in facilitating vesicle docking and fusion. These interactions are essential for the neurotransmitter release process which is part of the larger synaptic signaling pathway. CPLX2 modulates synaptic plasticity and exocytosis linking it to the regulation of synaptic strength and neural network activity.
Alterations in CPLX2 expression or function have been associated with neurological conditions like epilepsy and schizophrenia. Abnormal CPLX2 activity may lead to disrupted synaptic signaling contributing to the pathophysiology of these disorders. Additionally its connection with SNARE proteins such as SNAP-25 serves as a potential point of intersection where synaptic dysfunction can contribute to disease development. Understanding CPLX2’s influence on neurotransmission provides insights into therapeutic targets for synaptic disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunofluorescent analysis of 4% PFA fixed, 0.1% Triton X-100 in PBS permeabilzed SH-SY5Y (human neuroblastoma cell line from bone marrow) cells labeling CPLX2 with ab276059 at 1/60 dilution, 4°C overnight, followed by Goat Anti-rabbit IgG Alexa Fluor 488-conjugated secondary antibody (green). Cells were blocked with 10% serum prior incubation.
Intracellular flow cytometric analysis of SH-SY5Y (human neuroblastoma cell line from bone marrow) cells labeling CPLX2 with ab276059, followed byFITC-conjugated secondary antibody (black line) compared with a negative control (grey line).The cells were treated according to manufacturer's manual. The Fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com